Voronoi, Inc.

As South Korea aims to foster the development of global blockbuster drugs and top-tier internationalized biopharma firms in the coming years, amid limited financial and labor resources as well as othe

Disappointing news appeared to overflow in the South Korean biotech sector in the second quarter amid multiple returned assets from global partners, a lack of major new out-licensing deals, as well as

As South Korea seeks to foster the biohealth industry through various strategies including creating new markets, the Korea Health Industry Development Institute (KHIDI) is also making broad efforts in

Amid the ongoing global financial strains and a high interest rate environment, bioventures in South Korea are increasingly opting to raise funds through rights offerings, despite concerns over share